Arca
Skip to content
Tools
Tools

CD2: T-cell surface antigen CD2

CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on CD2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1

Approved1

  • Alefacept

Phase 30

    Phase 21

    • Siplizumab

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      AlefaceptApprovedAstellas PharmaProtein or peptideInhibitorT-cell surface antigen CD2 inhibitor0
      SiplizumabPhase 2ITB-Med LLCAntibodyInhibitorT-cell surface antigen CD2 inhibitor7

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
      A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney TransplantSiplizumabPhase 2RecruitingITB-Med LLCApr 2, 2026
      Tolerance Through Mixed Chimerism (Sip-Tego)SiplizumabEarly phase 1Active, not recruitingTatsuo Kawai, MD, PhDMay 14, 2025
      A Study of SIPLIZUMAB in AILD and LT PatientsSiplizumabPhase 1RecruitingElizabeth C. VernaJun 12, 2024
      Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.SiplizumabEarly phase 1RecruitingUniversity of Alabama at BirminghamMar 22, 2024
      A Study of TCD601 in the Induction of Tolerance in de Novo Liver TransplantationSiplizumabPhase 2Active, not recruitingITB-Med LLCAug 31, 2023
      Delayed Tolerance Through Mixed ChimerismSiplizumabPhase 1 / Phase 2RecruitingMassachusetts General HospitalJun 12, 2023
      Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGHSiplizumabPhase 1Active, not recruitingMassachusetts General HospitalSep 7, 2020

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Hypothyroidism0.46
      • Myxedema0.38
      • Psoriasis vulgaris0.38
      • Immune system disorder0.37
      • Pain0.37
      • Thyroid gland disorder0.33
      • Autoimmune thyroid disease0.31
      • Kidney disorder0.23

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2040, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P06729, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.